Harvest One’s Satipharm Makes First Shipment

Ryan Allway May 16th, 2017 News, Top News

The cannabis industry is rapidly growing around the world, including the research-driven cannabidiol (CBD) segment. Analysts believe that CBD-based products will generate between $2 billion and $3 billion in revenue by 2021 as researchers uncover the potential of the cannabinoid. At the same time, consumers will become more discerning and seek out the highest quality producers of CBD oils and capsules.

In this article, we will take a closer look at Harvest One Cannabis Inc.’s (TSX-V: HVST) Satipharm AG subsidiary and its progress in commercializing its Gelpell CBD capsules. We will also take a look at the company’s dual focus on developing both CBD and cannabis brands targeting Canada’s upcoming recreational cannabis and existing medical cannabis industries.

Emerging $3+ Billion Industry

The cannabis industry is booming thanks to the legalization of recreational marijuana across Canada and parts of the United States, but many consumers are looking for more than just a ‘high’ – they’re seeking the medical benefits of the plant.

While tetrahydrocannabinol (THC) has been widely studied for conditions like epilepsy, researchers are just starting to fully understand the benefits of cannabidiol (CBD). The lesser known non-psychoactive component of cannabis may have significantly greater health benefits and more than 800 studies have already been published on it this year. Consumers have also become increasingly aware as evidenced by the rapid growth in Google search traffic.

The Hemp Business Journal reckons that the market for CBD products could reach $2 billion by 2020, while GreenWave Advisors believes that it could grow even more to $3 billion by 2021. Either way, there’s little question that the market is rapidly growing, particularly given that consumers can access the benefits of CBDs without a prescription.

Pioneering Cannabis Delivery

Harvest One’s Satipharm AG subsidiary aims to become a leader in the development and production of dietary supplements that contain cannabidiol (CBD).

The company’s flagship product is the CBD Gelpell Microgel Capsules, which contains a controlled delivery system that enhances oral bioavailability. The capsules are manufactured under Good Manufacturing Practices (GMP) in Switzerland with medical cannabis grown under Good Agricultural and Collection Practices (GACP) in highly-controlled environments. The capsules are also tested to be completely THC-free.

The capsules have undergone a successful Phase I clinical trial for safety and bioavailability. As such, the product has already been approved by the health authorities and prescribing physicians in some countries for the treatment of approved medical conditions. These attributes set the product apart from other CBD capsule products that have imprecise dosing or a lack of quality control, as evidenced by the FDA’s past warning letters in the U.S.

In the future, the company plans to release additional products that include THC and other cannabinoids that could have beneficial properties.

Commercialization Progress

Harvest One recently announced that its Satipharm subsidiary made its first shipment of CBD Gelpell Microgel Capsules to its distribution partner in Australia.

The proprietary gastro-resistant microgel capsules are approved by prescribing physicians under Australian federal and state legislation for the treatment of various medical conditions. HL Pharma – the company’s distribution partner in the country – is ready for immediate distribution of the new product that is expected to be one of the first medical cannabis products available to approved prescribers in the country.

“Bringing Satipharm’s sophisticated products to international medical cannabis markets as legislations open up is an integral part of the company’s aggressive growth strategy,” said Harvest One CEO Andreas Gedeon in the press release announcing the deal. “The arrival of our capsules in Australia is great news for medical cannabis patients in the country. It also further manifests our first mover position as a truly global player in the industry.”

Looking Ahead

Harvest One Cannabis Inc. (TSX-V: HVST) represents a compelling investment opportunity within the cannabis industry. In addition to its Satipharm subsidiary, the company has two other businesses that operate across the entire cannabis value chain. Each business is strategically located in favorable jurisdictions with supportive regulatory frameworks, including its United Greeneries business that has secured a medical cannabis cultivation license in Canada.

For more information, visit the company’s website.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.